Literature DB >> 7944331

From esoteric theory to therapeutic antibodies.

T T Wu1.   

Abstract

Theoretical analyses of amino acid and nucleotide sequences of immunoglobulins have provided a unique approach to the understanding of structure and function of antibodies. Variability plots unambiguously identified that the antibody-combining site is formed by six short complementarity determining regions (CDRs), three each from light and heavy chains. Since three-dimensional (3-D) foldings of framework regions (FRs) are similar among different antibodies, the 3-D configurations of CDRs from a specific antibody can be predicted based on their amino acid sequences. The resulting structure forms a compact surface that fits the antigen molecule tightly. The third CDR of the heavy chain (CDRH3), which is coded by the D-minigene together with the N- and/or P-segments, appears to play a unique role in fine fitting between antibody and antigen molecules. In order to maintain biological activities, the grafting of mouse CDRs onto human FRs should closely match the human FR amino acid sequences with the original mouse antibody. Similarities between human and mouse FR sequences that have been preserved for over 20 million years of evolution can be a useful tool in humanizing mouse antibodies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944331     DOI: 10.1007/bf02787928

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  45 in total

1.  Docking by least-squares fitting of molecular surface patterns.

Authors:  D J Bacon; J Moult
Journal:  J Mol Biol       Date:  1992-06-05       Impact factor: 5.469

Review 2.  Catalytic antibodies.

Authors:  K M Shokat; P G Schultz
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Somatic hyperconversion diversifies the single Vh gene of the chicken with a high incidence in the D region.

Authors:  C A Reynaud; A Dahan; V Anquez; J C Weill
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

Review 4.  Structure and evolution of immunoglobulins.

Authors:  C Milstein; J R Pink
Journal:  Prog Biophys Mol Biol       Date:  1970       Impact factor: 3.667

5.  Construction of a three-dimensional model of the polypeptide backbone of the variable region of kappa immunoglobulin light chains.

Authors:  E A Kabat; T T Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1972-04       Impact factor: 11.205

6.  Three-dimensional structure of the Fab' fragment of a human immunoglobulin at 2,8-A resolution.

Authors:  R J Poljak; L M Amzel; H P Avey; B L Chen; R P Phizackerley; F Saul
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

7.  Structure of a lambda-type Bence-Jones protein at 3.5-A resolution.

Authors:  M Schiffer; R L Girling; K R Ely; A B Edmundson
Journal:  Biochemistry       Date:  1973-11-06       Impact factor: 3.162

8.  Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains.

Authors:  E A Kabat; T T Wu
Journal:  Ann N Y Acad Sci       Date:  1971-12-31       Impact factor: 5.691

9.  Structure and physical map of 64 variable segments in the 3'0.8-megabase region of the human immunoglobulin heavy-chain locus.

Authors:  F Matsuda; E K Shin; H Nagaoka; R Matsumura; M Haino; Y Fukita; S Taka-ishi; T Imai; J H Riley; R Anand
Journal:  Nat Genet       Date:  1993-01       Impact factor: 38.330

10.  An attempt to locate the non-helical and permissively helical sequences of proteins: application to the variable regions of immunoglobulin light and heavy chains.

Authors:  T T Wu; E A Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

View more
  1 in total

1.  Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.

Authors:  J Larkin; T A Lohr; L Elefante; J Shearin; R Matico; J-L Su; Y Xue; F Liu; C Genell; R E Miller; P B Tran; A-M Malfait; C C Maier; C J Matheny
Journal:  Osteoarthritis Cartilage       Date:  2015-03-20       Impact factor: 6.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.